Atlas Venture has been running for over 30 years and is one of the world's leading biotech-only VCs. The firm operates a two-fund model: Fund XIV ($450M, closed December 2024) for seed and Series A, and Opportunity Fund III ($400M, closed September 2025) for growth-stage follow-on.
The company-building track record is substantial — 78 startups launched through the incubator, with 42 IPOs and 37 M...
Chicago, United States
Boston, United States
Santa Monica, United States
San Francisco, United States
Boston, United States
Dublin, Ireland